XML 203 R162.htm IDEA: XBRL DOCUMENT
v3.20.2

Stockholders' Deficiency and Members' Equity (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC) (10-K) - USD ($) |  |  | 2 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | --- | ---
Sep. 23, 2019 | Nov. 07, 2018 | Dec. 31, 2018 | Dec. 31, 2018 | Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | Dec. 31, 2019 | Dec. 31, 2018 | Nov. 05, 2018
Preferred stock designated |  |  | 156,000 | 156,000 | 156,000 |  | 156,000 |  | 156,000 | 156,000 |
Debt instrument principal amount |  |  |  |  | $ 3,350,100 |  | $ 3,350,100 |  |  |  |
Share based compenation, expected term |  |  |  |  |  | 5 years 7 months 10 days |  | 5 years 8 months 23 days | 5 years 4 months 13 days | 7 years 22 days |
Share based compenation, volatility |  |  |  |  |  | 95.11% |  | 108.83% | 105.53% | 113.20% |
Share based compenation, risk-free rate |  |  |  |  |  | 1.39% |  | 1.70% | 1.68% | 2.87% |
Share based compenation, expected dividend rate |  |  |  |  |  | 0.00% |  | 0.00% | 0.00% | 0.00% |
Stock-based compensation |  |  |  |  | 53,000 | $ 63,000 | 135,000 | $ 172,000 | $ 206,000 | $ 443,000 |
Brooklyn Immunotherapeutics, LLC [Member] |  |  |  |  |  |  |  |  |  |  |
Shares to be issued |  |  |  |  |  |  |  |  |  |  | 171,781,743
Cash |  |  | $ 6,325,431 | $ 6,325,431 | $ 3,055,012 | $ 6,260,338 | 3,055,012 | 6,260,338 | 5,014,819 | 6,325,431 |
Stock-based compensation |  |  |  |  |  |  | 68,202 | $ 68,674 |  |  |
Brooklyn Immunotherapeutics, LLC [Member] | Successor [Member] |  |  |  |  |  |  |  |  |  |  |
Cash |  |  | 6,325,431 | $ 6,325,431 |  |  |  |  | 5,014,819 | $ 6,325,431 |
Number of restricted common units, shares |  |  |  | 4,125 |  |  |  |  |  |  |
Number of restricted common units, value |  |  |  | $ 366,094 |  |  |  |  |  |  |
Stock-based compensation |  |  | $ 20,248 | $ 20,248 |  |  |  |  | $ 91,689 |  |
Brooklyn Immunotherapeutics, LLC [Member] | Successor [Member] | Single Employee [Member] |  |  |  |  |  |  |  |  |  |  |
Number of restricted common units, shares | 125 |  |  |  |  |  |  |  |  |  |
Number of restricted common units, value | $ 11,094 |  |  |  |  |  |  |  |  |  |
Brooklyn Immunotherapeutics, LLC [Member] | Successor [Member] | Restricted Common Units [Member] |  |  |  |  |  |  |  |  |  |  |
Share price |  |  | $ 88.75 | $ 88.75 |  |  |  |  |  | $ 88.75 |
Vesting percentage | 25.00% |  |  |  |  |  |  |  |  |  |
Vesting term | 3 years |  |  |  |  |  |  |  |  |  |
Brooklyn Immunotherapeutics, LLC [Member] | Successor [Member] | Restricted Common Units [Member] | Single Employee [Member] |  |  |  |  |  |  |  |  |  |  |
Share price | $ 88.75 |  |  |  |  |  |  |  |  |  |
Brooklyn Immunotherapeutics, LLC [Member] | BITX Operating Agreement [Member] |  |  |  |  |  |  |  |  |  |  |
Shares issued |  |  |  |  |  |  |  |  | 100,000 |  |
Pro rata description |  |  |  |  |  |  |  |  | Any distributions are made to the members in the following order and priority: first, on a pro rata basis, to the holders of Class A Units, in proportion to the number of Class A Units held by each, until the Company has made aggregate distributions of $100 million; second, 75% on a pro rata basis to holders of Class A Units and Common Units, 15% on a pro rata basis to the holders of Class B Units and 10% on a pro rata basis to holders of Class C Units, until the Company has made aggregate distributions equal to $500 million; thereafter, 65% on a pro rata basis to holders of Class A Units and Common Units, 20% on a pro rata basis to the holders of Class B Units and 15% on a pro rata basis to holders of Class C Units. |  |
Debt instrument principal amount |  |  | $ 9,953,930 | $ 9,953,930 |  |  |  |  |  | $ 9,953,930 |
Cash |  |  | $ 7,587,584 | $ 7,587,584 |  |  |  |  | $ 7,808,250 | 7,587,584 |
Exchanged notes payable and interest amount |  |  |  |  |  |  |  |  |  | 1,516,346 |
Subscriptions receivable |  |  |  |  |  |  |  |  |  | 850,000 |
Payments in excess of capital calls |  |  |  |  |  |  |  |  |  | $ 638,575 |
Investor deposits |  |  |  |  |  |  |  |  | 410,512 |  |
Equity value |  | $ 22,000,000 |  |  |  |  |  |  |  |  |
Share based compenation, expected term |  | 3 years 6 months |  |  |  |  |  |  |  |  |
Share based compenation, volatility |  | 100.00% |  |  |  |  |  |  |  |  |
Share based compenation, risk-free rate |  | 3.01% |  |  |  |  |  |  |  |  |
Share based compenation, expected dividend rate |  | 0.00% |  |  |  |  |  |  |  |  |
Brooklyn Immunotherapeutics, LLC [Member] | BITX Operating Agreement [Member] | Successor [Member] |  |  |  |  |  |  |  |  |  |  |
Stock-based compensation |  |  |  |  |  |  |  |  | 91,689 |  |
Brooklyn Immunotherapeutics, LLC [Member] | Series A Preferred Stock [Member] |  |  |  |  |  |  |  |  |  |  |
Preferred stock designated |  |  |  |  |  |  |  |  |  |  | 160,000
Brooklyn Immunotherapeutics, LLC [Member] | Series B Preferred Stock [Member] |  |  |  |  |  |  |  |  |  |  |
Preferred stock designated |  |  |  |  |  |  |  |  |  |  | 54,000
Brooklyn Immunotherapeutics, LLC [Member] | Series C Preferred Stock [Member] |  |  |  |  |  |  |  |  |  |  |
Preferred stock designated |  |  |  |  |  |  |  |  |  |  | 41,567,743
Brooklyn Immunotherapeutics, LLC [Member] | Series D Preferred Stock [Member] |  |  |  |  |  |  |  |  |  |  |
Preferred stock designated |  |  |  |  |  |  |  |  |  |  | 80,000,000
Brooklyn Immunotherapeutics, LLC [Member] | Series A, Series B and Series C Convertible Preferred Stock [Member] |  |  |  |  |  |  |  |  |  |  |
Exchange of preferred stock into common stock |  |  |  |  |  |  |  |  |  |  | 16,771,866
Brooklyn Immunotherapeutics, LLC [Member] | Class A Units [Member] |  |  |  |  |  |  |  |  |  |  |
Share issued during the period new issue, value |  |  |  |  |  |  | $ 5,024,313 |  | $ 8,218,762 |  |
Brooklyn Immunotherapeutics, LLC [Member] | Class A Units [Member] | BITX Operating Agreement [Member] |  |  |  |  |  |  |  |  |  |  |
Shares issued |  |  |  |  |  |  |  |  | 65,000 | 65,000 |
Share issued during the period new issue, value |  |  |  |  |  |  |  |  | $ 100,000,000 |  |
Capital commitments |  |  |  |  |  |  |  |  |  | $ 22,447,005 |
Number of shares issued for service |  |  |  |  |  |  |  |  |  | $ 5,000 |
Exchanged notes payable and interest amount |  |  |  |  |  |  |  |  | 8,218,762 |  |
Payments in excess of capital calls |  |  |  |  |  |  |  |  | $ 437,500 |  |
Brooklyn Immunotherapeutics, LLC [Member] | Class B Units [Member] | BITX Operating Agreement [Member] |  |  |  |  |  |  |  |  |  |  |
Shares issued |  | 15,000 |  |  |  |  |  |  | 15,000 |  |
Share issued during the period new issue, value |  | $ 1,400,000 |  |  |  |  |  |  |  |  |
Brooklyn Immunotherapeutics, LLC [Member] | Class C Units [Member] | BITX Operating Agreement [Member] |  |  |  |  |  |  |  |  |  |  |
Shares issued |  | 10,000 |  |  |  |  |  |  | 10,000 |  |
Share issued during the period new issue, value |  | $ 1,000,000 |  |  |  |  |  |  |  |  |
Brooklyn Immunotherapeutics, LLC [Member] | Common Units [Member] | BITX Operating Agreement [Member] |  |  |  |  |  |  |  |  |  |  |
Shares issued |  |  |  |  |  |  |  |  | 10,000 |  |
Brooklyn Immunotherapeutics, LLC [Member] | Common Stock [Member] |  |  |  |  |  |  |  |  |  |  |
Shares to be issued |  |  |  |  |  |  |  |  |  |  | 50,000,000
Brooklyn Immunotherapeutics, LLC [Member] | Preferred Stock [Member] |  |  |  |  |  |  |  |  |  |  |
Shares to be issued |  |  |  |  |  |  |  |  |  |  | 121,781,743

X
- Definition Capital commitments. + References No definition available. + Details
Name: | NTN_CapitalCommitments
Namespace Prefix: | NTN_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Equity value. + References No definition available. + Details
Name: | NTN_EquityValue
Namespace Prefix: | NTN_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Exchange of preferred stock into common stock. + References No definition available. + Details
Name: | NTN_ExchangeOfPreferredStockIntoCommonStock
Namespace Prefix: | NTN_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Pro rata description. + References No definition available. + Details
Name: | NTN_ProRataDescription
Namespace Prefix: | NTN_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Shares to be issued. + References No definition available. + Details
Name: | NTN_SharesToBeIssued
Namespace Prefix: | NTN_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Subscriptions receivable. + References No definition available. + Details
Name: | NTN_SubscriptionsReceivable
Namespace Prefix: | NTN_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 210 -Section 45 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 210 -Section 45 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840 + Details
Name: | us-gaap_Cash
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586 + Details
Name: | us-gaap_DebtConversionConvertedInstrumentAmount1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Face (par) amount of debt instrument at time of issuance. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400 + Details
Name: | us-gaap_DebtInstrumentFaceAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.12) -URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878 + Details
Name: | us-gaap_Deposits
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_PreferredStockSharesAuthorized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585 + Details
Name: | us-gaap_RepaymentsOfDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of noncash expense for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 + Details
Name: | us-gaap_ShareBasedCompensation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The risk-free interest rate assumption that is used in valuing an option on its own shares. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of vesting of award under share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details
Name: | us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.2) -URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809 + Details
Name: | us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders. + References No definition available. + Details
Name: | us-gaap_StockIssuedDuringPeriodValueIssuedForServices
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Aggregate value of stock related to Restricted Stock Awards issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=NTN_BrooklynImmunotherpeuticsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=NTN_SuccessorsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=NTN_SingleEmployeeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=NTN_BITXOperatingAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=NTN_SeriesASeriesBandSeriesCConvertiblePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=NTN_ClassAUnitsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=NTN_ClassBUnitsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=NTN_ClassCUnitsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=NTN_CommonUnitsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |